Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?
Level V
Where this comes from
- Record sourced from PubMed, PMID 20467430.
- Also identified by DOI 10.1038/ki.2010.77.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Vitamin D receptor agonists (VDRAs) inhibit the renin-angiotensin system (RAS) and reduce podocyte loss and fibrosis over and above RAS blockade. Several studies in humans show that VDRAs are antiproteinuric and have the potential to delay the progression of renal disease. Whether VDRAs will accomplish this goal among proteinuric patients with chronic kidney disease needs to be tested in randomized controlled trials.
Medical subject headings
- Angiotensin II Type 1 Receptor Blockers
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Ergocalciferols
- Kidney Glomerulus
- Losartan
- Receptors, Calcitriol
- Vitamins